title: Thirteen years follow-up after radical transsternal thymectomy for myasthenia gravis. Do short-term results predict long-term outcome?
abstract: OBJECTIVE
  Long-term evaluation of efficacy and quality of life after radical surgical approach for myasthenia gravis (MG). Comparison between short-term follow-up and long-term outcome.
  
  
  METHODS
  All patients (n=26, 16 men and 10 women, mean age: 40.7 years) underwent total transsternal thymectomy for MG between 1986 and 1989. Prospective analysis of the patients for short-term follow-up (mean 22.4 months) was published in 1991. The same group of patients was reevaluated in 2001 (range of follow-up 11.4-15.2 years) and assessed according to the classification of Osserman and Oosterhuis.
  
  
  RESULTS
  Mean follow-up was 13.0 years (range 11.4-15.2 years). Two patients were lost from follow-up and one died 4 years after thymectomy for reasons unrelated to MG (n=23). No early or late postoperative mortality was observed. One sternal osteomyelitis occurred. Late postoperative morbidity included sternal instabilities (n=2), mild residual thoracic pain (n=6), and hypertrophic scars (n=7). Five patients were rehospitalized for aggravating MG and needed plasmapheresis (n=3) and intubation (n=1). Thirteen patients (56.5%) showed objective clinical improvement, including six patients (26.1%) with complete remission. Eleven patients (47.8%) do not take any medication at all. Because some late relapse may occur several years after operation, the rate of improvement decreased slightly, whereas the difference between short and long-term follow-up was not statistically significant (P=0.405). Twenty patients (87%) returned to work, including part-time occupation (n=4). Fourteen patients (61%) are performing sports regularly.
  
  
  CONCLUSIONS
  Our data confirm that radical, transsternal thymectomy is an effective and safe therapeutic modality for MG. Short-term results seem to deteriorate over time, therefore long-term studies for minimally invasive approaches have to prove equal results before replacing the standard procedure.
authors.affiliation: Division of General Thoracic Surgery, University Hospital, 3030 Bern, Switzerland.
authors.forename: T
authors.initials: T
authors.lastname: Roth
authors.forename: R
authors.initials: R
authors.lastname: Ackermann
authors.forename: R
authors.initials: R
authors.lastname: Stein
authors.forename: R
authors.initials: R
authors.lastname: Inderbitzi
authors.forename: K
authors.initials: K
authors.lastname: Rösler
authors.forename: R A
authors.initials: RA
authors.lastname: Schmid
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000906:Antibodies / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D009157:Myasthenia Gravis / Q000453:epidemiology / Q000401:mortality / Q000601:surgery*; D011183:Postoperative Complications / Q000209:etiology; D011237:Predictive Value of Tests; D011788:Quality of Life; D011950:Receptors, Cholinergic / Q000276:immunology; D012720:Severity of Illness Index; D012737:Sex Factors; D013249:Sternum / Q000601:surgery*; D013557:Switzerland / Q000453:epidemiology; D013934:Thymectomy / Q000379:methods; D013950:Thymus Gland / Q000033:anatomy & histology / Q000473:pathology; D013995:Time; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D011950:Receptors, Cholinergic